# A Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics of ELX-02

> **NCT03776539** · PHASE1 · COMPLETED · sponsor: **Eloxx Pharmaceuticals, Inc.** · enrollment: 24 (actual)

## Conditions studied

- Impaired Renal Function

## Interventions

- **DRUG:** ELX-02

## Key facts

- **NCT ID:** NCT03776539
- **Lead sponsor:** Eloxx Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-04
- **Primary completion:** 2019-07-30
- **Final completion:** 2019-08-07
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2021-04-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03776539

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03776539, "A Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics of ELX-02". Retrieved via AI Analytics 2026-09-28 from https://api.ai-analytics.org/clinical/NCT03776539. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*